TheraNest vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management and therapy notes software for mental health practitioners, acquired by Therapy Brands. Serves solo practices, group practices, and agencies.
About
TheraNest is a cloud-based practice management and clinical documentation platform for mental health practitioners, including therapists, social workers, counselors, and psychologists. Originally founded as an independent company, TheraNest was acquired by Therapy Brands, a technology roll-up focused on behavioral health software, which also owns Therapy Brands, ICANotes, and other mental health practice management systems. TheraNest serves a broad range of practice types from solo practitioners to large group practices and nonprofit agencies.\n\nThe platform provides scheduling, billing, telehealth, clinical notes, treatment planning, and client portal functionality in a unified interface. TheraNest is particularly recognized for its affordability and straightforward pricing model, which has made it a popular choice for practices with tight administrative budgets and those serving Medicaid populations. The product supports both individual and group therapy documentation workflows, including co-signature and supervision features relevant to practices employing pre-licensed associates.\n\nAs part of the Therapy Brands portfolio, TheraNest benefits from shared infrastructure investment and cross-selling opportunities, while maintaining its standalone brand and product identity. The mental health EHR market is competitive, with SimplePractice, TherapyNotes, and Jane App also vying for the small-to-mid-size practice segment. TheraNest's acquisition has allowed it to invest in product development while leveraging Therapy Brands' broader customer relationships and compliance infrastructure.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.